In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
As of close of business last night, Mineralys Therapeutics Inc’s stock clocked out at $14.0, down -1.69% from its previous closing price of $14.24. In other words, the price has decreased by -$1.69 from its previous closing price. On the day, 0.51 million shares were traded. MLYS stock price reached its highest trading level at $14.35 during the session, while it also had its lowest trading level at $13.785.
Ratios:
To gain a deeper understanding of MLYS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 26.48 and its Current Ratio is at 26.48. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on June 11, 2025, initiated with a Hold rating and assigned the stock a target price of $15.
On July 10, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30.
On April 02, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $30.Goldman initiated its Buy rating on April 02, 2024, with a $30 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 13 ’25 when Rodman David Malcom sold 11,366 shares for $14.60 per share. The transaction valued at 165,931 led to the insider holds 101,651 shares of the business.
Rodman David Malcom bought 11,366 shares of MLYS for $165,931 on Jun 13 ’25. On May 14 ’25, another insider, Rodman David Malcom, who serves as the Chief Medical Officer of the company, sold 11,366 shares for $15.29 each. As a result, the insider received 173,774 and left with 106,669 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MLYS now has a Market Capitalization of 928096384 and an Enterprise Value of 569428032.
Stock Price History:
The Beta on a monthly basis for MLYS is -0.22, which has changed by 0.19658124 over the last 52 weeks, in comparison to a change of 0.12463009 over the same period for the S&P500. Over the past 52 weeks, MLYS has reached a high of $18.38, while it has fallen to a 52-week low of $8.24. The 50-Day Moving Average of the stock is -5.57%, while the 200-Day Moving Average is calculated to be 8.23%.
Shares Statistics:
It appears that MLYS traded 936.87K shares on average per day over the past three months and 1040210 shares per day over the past ten days. A total of 64.88M shares are outstanding, with a floating share count of 40.61M. Insiders hold about 37.70% of the company’s shares, while institutions hold 65.72% stake in the company. Shares short for MLYS as of 1749772800 were 6168786 with a Short Ratio of 6.58, compared to 1747267200 on 7206718. Therefore, it implies a Short% of Shares Outstanding of 6168786 and a Short% of Float of 12.509999999999998.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
